India takes its first step towards opening door to Controlled Human Infection Studies
The HinduIndia has taken its first step to introduce Controlled Human Infection Studies, used in many countries for vaccine and treatment development. “This paper is aimed at addressing a variety of ethical issues so that research can be conducted in India without compromising on ethical principles while ensuring the protection of human participants,” notes ICMR. ICMR notes that India has so far stayed away from CHIS, because regardless of the potential scientific benefits, these studies are ethically sensitive and raise concerns about contentious research ethics — issues like deliberate harm, possible disproportionate payment and hence inducements, third-party risk, withdrawal from the study and research with vulnerable participants. CHIS is a relatively new research model that helps provide unique insights into disease pathogenesis and can accelerate the development of novel medical interventions, said ICMR.